HELLP Syndrome

• Endothelial Dysfunction and Platelet Consumption: Abnormal placentation and incomplete remodeling of spiral arteries trigger release of vasoactive substances including soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), which antagonize vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-β). This leads to generalized endothelial activation characterized by increased vascular permeability, microangiopathy, and platelet microthrombi formation. Activated endothelium directly causes platelet consumption exceeding bone marrow production, resulting in thrombocytopenia (typically platelet count <100,000/μL). The microthrombi physically occlude renal glomeruli, hepatic sinusoids, and cerebral microvessels, explaining the triad of organ involvement.

• Hemolysis and Microangiopathic Hemolytic Anemia (MAHA): In the setting of microthrombi and narrowed vascular lumens, red blood cells undergo mechanical deformation and fragmentation as they traverse abnormal microvasculature, creating schistocytes (fragmented RBCs) visible on peripheral smear. This microangiopathic hemolytic anemia is non-immune mediated and distinct from other causes of hemolysis. Hemolysis is confirmed by elevation of lactate dehydrogenase (LDH) >600 IU/L (often >1400 IU/L in HELLP), low serum haptoglobin (<25 mg/dL), elevated indirect bilirubin, and elevated reticulocyte count reflecting bone marrow response. The degree of hemolysis correlates with disease severity and is part of the pathologic cascade rather than a primary mechanism.

• Hepatic Endothelial Injury and Cytotoxicity: Placental ischemia triggers release of antiangiogenic factors and inflammatory cytokines that cause sinusoidal endothelial injury and hepatocellular dysfunction. Platelet microthrombi preferentially deposit in hepatic sinusoids, causing periportal necrosis and hemorrhage on histology. This leads to hepatic dysfunction manifested clinically by elevated transaminases (AST/ALT typically >2× upper limit of normal, often >10× ULN in severe HELLP), elevated gamma-glutamyl transferase (GGT), and in severe cases, right upper quadrant pain from hepatic capsular distension or rupture. Unlike primary hepatic disease, albumin and PT/INR typically remain relatively preserved initially, though DIC can rapidly develop. The fatty infiltration and mitochondrial dysfunction observed histologically reflect cytotoxic mechanisms beyond simple ischemia.

• Renal Endothelial Disease and Acute Kidney Injury: Glomerular endothelial swelling and platelet microthrombi deposition cause glomerular capillary narrowing and reduced glomerular filtration. This results in acute kidney injury (development or worsening of hypercreatinine in approximately 50% of HELLP cases) without proteinuria elevation proportionate to creatinine rise. The pathology resembles hemolytic uremic syndrome (HUS) with thrombotic microangiopathy rather than typical preeclampsia. Direct endothelial injury also increases vascular permeability in the lungs, predisposing to acute respiratory distress syndrome (ARDS) and pulmonary edema.

• Cerebral Complications: Severe endothelial dysfunction in cerebral vasculature can precipitate cerebral vasospasm, posterior reversible encephalopathy syndrome (PRES), and eclampsia. The breakdown of the blood-brain barrier by inflammatory mediators and vasoactive substances permits cerebral edema and may culminate in seizures, hemorrhagic stroke, or intracranial hemorrhage. Platelets and fibrin deposition may contribute to both thrombotic and hemorrhagic events.

• Preeclampsia (Primary Risk Factor): HELLP syndrome occurs exclusively within the context of preeclampsia or gestational hypertension. Approximately 10-20% of women with preeclampsia progress to HELLP syndrome, with risk substantially elevated in those with severe features (blood pressure ≥160/110 mmHg, symptomatic manifestations, or abnormal laboratory values). The presence of clinical or laboratory preeclampsia features before HELLP manifestation is essential for diagnosis, though rare atypical HELLP cases present without antecedent hypertension.

• Nulliparity: Nulliparous women have substantially increased HELLP risk compared to multiparous women, reflecting increased risk for abnormal placentation and immune maladaptation in first pregnancies. This is consistent with the broader epidemiology of preeclampsia.

• Maternal Age >35 Years: Advanced maternal age confers approximately 2-fold increased risk, likely related to increased vascular stiffness, preexisting endothelial dysfunction, and higher rates of comorbidities. Women >40 years have particularly elevated risk.

• Preexisting Hypertension or Chronic Kidney Disease: Women with chronic hypertension have 4-5 fold increased preeclampsia risk and substantially higher HELLP risk when preeclampsia develops. Similarly, those with chronic kidney disease (eGFR <60 mL/min/1.73m²) or diabetic nephropathy demonstrate heightened risk due to preexisting glomerular dysfunction and endothelial abnormalities.

• Multiple Gestations: Twin pregnancies and higher-order multiples carry 2-3 fold increased preeclampsia risk and consequently elevated HELLP risk. The greater placental mass and increased placental ischemia contribute to more robust release of antiangiogenic factors.

• Antiphospholipid Syndrome and Thrombophilias: Women with antiphospholipid antibodies or inherited thrombophilias (Factor V Leiden, prothrombin G20210A mutation, homozygous methylenetetrahydrofolate reductase [MTHFR] deficiency) demonstrate elevated preeclampsia and HELLP risk. The exact mechanisms remain incompletely understood but likely involve placental microthrombosis and enhanced inflammatory responses.

• Maternal Metabolic/Inflammatory Conditions: Obesity (BMI >30 kg/m²), type 2 diabetes mellitus, systemic lupus erythematosus (SLE), and other chronic inflammatory states increase preeclampsia and HELLP risk through heightened baseline endothelial activation and inflammatory tone.

• African American and Hispanic Ethnicity: African American women demonstrate 2-3 fold increased preeclampsia incidence compared to non-Hispanic white women, with higher HELLP frequency in this population. Hispanic ethnicity also confers modestly increased risk. Genetic, environmental, and socioeconomic factors contribute to these disparities.

• Prior Preeclampsia or HELLP Syndrome: Women with previous preeclampsia have 25-65% recurrence risk in subsequent pregnancies; prior HELLP carries 20-30% risk of recurrence as HELLP or preeclampsia. This suggests persistent underlying susceptibility factors.

• Previous Fetal Loss or Placental Pathology: Prior intrauterine fetal death, placental abruption, or small-for-gestational-age delivery increases HELLP risk in subsequent pregnancies, possibly reflecting persistent placentation abnormalities.

• Right Upper Quadrant or Epigastric Pain: Present in 40-60% of cases, this represents the most specific symptom suggesting hepatic involvement. Pain results from hepatic capsular distension from sinusoidal thrombosis and hepatocellular edema, or from frank hepatic microhemorrhages and infarction. Pain typically develops acutely over hours and may be accompanied by nausea and vomiting (40-50% of cases). Severe persistent pain warrants urgent evaluation for hepatic rupture, a catastrophic complication. Some patients describe the pain as radiating to the right shoulder tip (peritoneal irritation pattern).

• Headache: Occurs in 30-60% of cases and may indicate cerebral endothelial dysfunction, hypertensive emergency, or impending eclampsia. Headaches are typically frontal or occipital, persistent, and unresponsive to standard analgesics. Migraine-type headaches may progress to thunderclap headache if intracranial hemorrhage develops.

• Visual Disturbances: Photopsia (flashing lights), scotomas, blurred vision, or visual loss occur in 10-20% of cases and indicate retinal vasculitis or posterior reversible encephalopathy syndrome (PRES). These symptoms warrant urgent evaluation and are eclampsia precursors.

• Malaise, Fatigue, and General Illness Feeling: Nonspecific but common, reflecting systemic endothelial dysfunction and inflammatory state. Many patients report feeling "unwell" in the days preceding clinical recognition.

• Pulmonary Symptoms: Dyspnea, orthopnea, and chest pain develop in 5-10% of cases from pulmonary edema (cardiogenic from fluid overload and diastolic dysfunction, or non-cardiogenic from increased capillary permeability and ARDS). Pulmonary edema in HELLP often occurs after aggressive fluid administration in labor and delivery settings.

• Seizures and Neurologic Symptoms: Eclampsia (seizures in the setting of preeclampsia) occurs in 10-20% of HELLP cases. Preceding symptoms include severe headache, visual disturbances, hyperreflexia, and clonus. Focal neurologic deficits, altered mental status, or loss of consciousness may indicate intracranial hemorrhage or cerebral infarction.

• Bleeding Manifestations: Petechiae, purpura, bleeding from mucous membranes, or bleeding from intravenous sites suggest DIC development with consumptive thrombocytopenia and coagulopathy. Vaginal bleeding or excessive postpartum hemorrhage may be first manifestation in postpartum HELLP.

• Physical Examination Findings:
• Hypertension: Blood pressure typically ≥140/90 mmHg, frequently >160/110 mmHg (severe range). Some patients have baseline hypertension that increases further.
• Hyperreflexia and Clonus: Brisk deep tendon reflexes (3-4+) and ankle clonus or patellar clonus indicate severe CNS irritability and increased seizure risk; clonus is present in >50% of women with preeclampsia with severe features.
• Right Upper Quadrant Tenderness: Direct palpation over the liver elicits pain, reflecting hepatic inflammation. Severe hepatic involvement may cause palpable hepatomegaly.
• Edema: Nonpitting facial, hand, and lower extremity edema are frequent but nonspecific findings.
• Altered Mental Status: Drowsiness, confusion, or agitation in severe cases.

• Important Clinical Variants:
• Antepartum HELLP (occurring before labor): Most common presentation (70% of cases), typically third trimester. Requires urgent delivery planning.
• Intrapartum HELLP (developing during active labor): Approximately 10-15% of cases.
• Postpartum HELLP (within 72 hours after delivery, most commonly within 48 hours): Approximately 10-15% of cases. Can be particularly deceptive as preeclampsia monitoring often decreases after delivery.
• Atypical HELLP (without antecedent hypertension or proteinuria): Rare (<5% of HELLP cases), presents diagnostic challenge. May be confused with other microangiopathies or liver disease. Diagnosis hinges on findings of microangiopathic hemolytic anemia with thrombocytopenia in a pregnant/postpartum woman.

• Clinical Context: Any pregnant or postpartum woman (typically >20 weeks gestation, but earlier presentations rare) presenting with right upper quadrant pain, epigastric pain, headache, visual symptoms, or nonspecific malaise with hypertension should raise suspicion for HELLP. Symptoms occurring in the setting of preeclampsia substantially elevate probability. Some cases present after apparently uncomplicated delivery when monitoring decreases.

• Complete Blood Count (CBC) - Platelet Count and Evidence of Hemolysis:
• Platelet count <100,000/μL (often <50,000 μL in severe cases) representing the "L" component. Thrombocytopenia must be acute (compare to first trimester baseline if available, as some pregnant women have mild gestational thrombocytopenia). Peripheral smear review is essential and reveals schistocytes (fragmented RBCs), which are pathognomonic for microangiopathic hemolysis.
• Hemoglobin drop of >1.2 g/dL from baseline or absolute hemoglobin <10 g/dL in some classification systems, though anemia alone is not diagnostic.
• Elevated reticulocyte count (>2.5%) reflecting bone marrow response to hemolysis.

• Peripheral Blood Smear: Must be reviewed when HELLP is suspected. Findings include schistocytes (helmet cells, triangular cells, fragmented cells), polychromasia, and nucleated RBCs. Absence of schistocytes makes HELLP diagnosis questionable and should prompt alternative diagnostic consideration.

• Hemolysis Markers:
• Lactate dehydrogenase (LDH) >600 IU/L (typically >1400 IU/L in clinically significant hemolysis), representing the "H" component of HELLP. LDH is more sensitive than AST for hemolysis in preeclampsia but must be distinguished from hepatic source of elevation.
• Serum haptoglobin <25 mg/dL (or undetectable): Haptoglobin binds free hemoglobin from hemolyzed RBCs; low levels confirm intravascular hemolysis. Haptoglobin may remain normal in milder hemolysis.
• Elevated indirect/unconjugated bilirubin (typically <3 mg/dL to avoid confusing with hepatic dysfunction).
• Reticulocyte count >2% indicating bone marrow response.

• Liver Function Tests - Elevated Liver Enzymes:
• Aspartate aminotransferase (AST) >2× upper limit of normal (typically >70 IU/L, often >150 IU/L in severe HELLP), representing the "E" component. AST elevation typically exceeds ALT elevation (reflecting hepatocellular injury pattern).
• Alanine aminotransferase (ALT) elevation, typically less pronounced than AST.

Immediate stabilisation (first hour)

• Maternal-fetal triage: admit to labor and delivery with continuous fetal monitoring, serial CBC/LFT/creatinine/coagulation studies every 6-12 hours, strict intake-output, and large-bore IV access with type and screen. ACOG (Practice Bulletin No. 222, Gestational Hypertension and Preeclampsia) treats HELLP as preeclampsia with severe features.
• Magnesium sulfate: seizure prophylaxis, not an antihypertensive. Standard regimen is a 4-6 g IV load over 20-30 minutes followed by 1-2 g/hr infusion, continued through delivery and for ~24 hours postpartum. It raises the seizure threshold by antagonizing NMDA receptors and relieving cerebral vasospasm. Reduce dosing and follow levels in renal impairment.
• Antihypertensives for acute-onset severe hypertension (systolic ≥160 or diastolic ≥110 mmHg persisting ≥15 minutes) — ACOG Committee Opinion on emergent therapy recommends treatment within 30-60 minutes with IV labetalol, IV hydralazine, or immediate-release oral nifedipine. Goal is a controlled reduction to roughly 140-150/90-100 mmHg, not normotension, to preserve uteroplacental perfusion.
• Judicious fluids: leaky endothelium means aggressive crystalloid precipitates pulmonary edema.

Definitive management

• Delivery is the only cure. ACOG advises delivery after maternal stabilization at ≥34 weeks, or at any gestational age for maternal instability, DIC, abruption, non-reassuring fetal status, or hepatic hematoma.
• Antenatal corticosteroids (betamethasone) at <34 weeks for fetal lung maturity; delay delivery 24-48 hours only if mother and fetus are stable. Corticosteroids given to treat HELLP itself produce a transient platelet rise but no proven maternal outcome benefit.
• Route: vaginal delivery is acceptable if the cervix is favorable; cesarean is for obstetric indications.
• Blood products: transfuse platelets for active bleeding or before cesarean when the count is markedly low; correct DIC with FFP/cryoprecipitate.

Avoid

• ACE inhibitors/ARBs (fetotoxic — captopril and all ACEIs are contraindicated in pregnancy), methylergonovine for postpartum hemorrhage in hypertensive women, and neuraxial anesthesia with significant thrombocytopenia or coagulopathy (epidural hematoma risk).

Maternal emergencies

• Hepatic subcapsular hematoma and rupture (emergency): periportal necrosis and sinusoidal hemorrhage dissect beneath Glisson capsule. Signals are severe RUQ or right shoulder pain, sudden hypotension/tachycardia out of proportion to visible bleeding, and a falling hematocrit; free fluid on FAST or CT confirms rupture. Management is massive transfusion plus laparotomy with packing or hepatic artery embolization.
• Disseminated intravascular coagulation (emergency): endothelial tissue factor exposure consumes clotting factors. Look for oozing from IV sites, falling fibrinogen, rising D-dimer, and prolonged PT/aPTT — fibrinogen is normal in uncomplicated HELLP, so a low value is the alarm.
• Placental abruption: decidual microvascular thrombosis and infarction; painful vaginal bleeding, tetanic uterus, category III tracing.
• Eclampsia, PRES, and intracranial hemorrhage (emergency): cerebral vasospasm with blood-brain barrier breakdown; heralded by unrelenting headache, scotomata, clonus, then seizure or focal deficit. Posterior white matter edema on MRI is PRES.
• Pulmonary edema and ARDS: increased capillary permeability compounded by iatrogenic fluid loading; hypoxemia, orthopnea, diffuse infiltrates.
• Acute kidney injury: glomerular thrombotic microangiopathy; oliguria with rising creatinine, occasionally requiring dialysis. Most recover renal function.
• Postpartum hemorrhage from thrombocytopenia and coagulopathy, and wound hematoma after cesarean.

Treatment-related

• Magnesium toxicity (emergency): loss of deep tendon reflexes precedes respiratory depression, then cardiac arrest. Monitor reflexes, respiratory rate, and urine output; antidote is IV calcium gluconate. Risk rises sharply with oliguria.
• Overshoot hypotension from IV antihypertensives, causing fetal bradycardia via reduced uteroplacental perfusion.
• Transfusion reactions and volume overload from blood product resuscitation.

• The classic stem: third-trimester (or first-week-postpartum) woman with right upper quadrant/epigastric pain, nausea, malaise, hypertension, and a platelet count under 100,000/μL. Order LDH, haptoglobin, AST/ALT, and a peripheral smear — schistocytes seal the diagnosis.
• Single best next step: stabilize, then deliver. Magnesium sulfate for seizure prophylaxis and IV labetalol or hydralazine for severe-range pressures run concurrently, but per ACOG the definitive treatment is delivery — expectant management past 34 weeks is the wrong answer.
• Corticosteroid trap: betamethasone at <34 weeks is for fetal lung maturity, not to treat HELLP. Dexamethasone transiently bumps the platelet count without improving maternal outcomes — do not pick it as the therapeutic answer.
• The association examiners love: sudden hypotension, shoulder-tip pain, and a falling hematocrit in HELLP = hepatic subcapsular hematoma with rupture — surgical emergency, not "increase the magnesium."
• Fibrinogen is the discriminator: normal in uncomplicated HELLP. Low fibrinogen plus hypoglycemia, hyperammonemia, and prolonged INR points to acute fatty liver of pregnancy instead.
• Distractors to reject: TTP (fever, prominent neurologic findings, ADAMTS13 activity <10%, minimal liver enzyme elevation) and atypical HUS (renal failure dominant, persists postpartum) — both respond to plasma exchange or eculizumab, not delivery.
• Timing pitfall: up to a fifth of cases present postpartum, and atypical HELLP can occur without hypertension or proteinuria. Absence of the classic preeclampsia picture does not exclude it.
• Magnesium is not an antihypertensive, and loss of patellar reflexes is the earliest sign of toxicity — stop the infusion and give calcium gluconate.
• Never an ACE inhibitor in pregnancy, and avoid methylergonovine for postpartum hemorrhage in these hypertensive patients.